450 related articles for article (PubMed ID: 18978703)
1. Prostate cancer screening.
Med Lett Drugs Ther; 2008 Nov; 50(1298):85-6. PubMed ID: 18978703
[No Abstract] [Full Text] [Related]
2. Prostate specific antigen and screening for early prostate cancer.
Davidson P
N Z Med J; 2001 Apr; 114(1129):150. PubMed ID: 11400919
[No Abstract] [Full Text] [Related]
3. Screening for prostate cancer.
Benbassat J
Isr J Med Sci; 1995 Sep; 31(9):579-80. PubMed ID: 7558786
[No Abstract] [Full Text] [Related]
4. Screening for prostate cancer.
Ruffin MT
J Fam Pract; 1999 Aug; 48(8):581-2. PubMed ID: 10496634
[No Abstract] [Full Text] [Related]
5. "Screening for prostate cancer".
Gohagan JK; Kramer BS; Greenwald P
Am J Prev Med; 1994; 10(4):245-6. PubMed ID: 7528519
[No Abstract] [Full Text] [Related]
6. Editorial comment on: Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).
Terris MK
Eur Urol; 2009 Feb; 55(2):392; discussion 393. PubMed ID: 18353530
[No Abstract] [Full Text] [Related]
7. An open letter to the American Society of Clinical Oncology.
Green S; Crowley J; Blumenstein B; Benedetti J
J Clin Oncol; 1998 Oct; 16(10):3478. PubMed ID: 9779727
[No Abstract] [Full Text] [Related]
8. The Japanese guideline for prostate cancer screening.
Hamashima C; Nakayama T; Sagawa M; Saito H; Sobue T
Jpn J Clin Oncol; 2009 Jun; 39(6):339-51. PubMed ID: 19346535
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer screening: is it possible to explain diametrically opposed views?
Richardson A
N Z Med J; 2005 Feb; 118(1209):U1289. PubMed ID: 15711622
[No Abstract] [Full Text] [Related]
10. Stratifying risk--the U.S. Preventive Services Task Force and prostate-cancer screening.
Schröder FH
N Engl J Med; 2011 Nov; 365(21):1953-5. PubMed ID: 22029756
[No Abstract] [Full Text] [Related]
11. ACP issues guidelines on the early detection of prostate cancer and screening for prostate cancer.
Rose VL
Am Fam Physician; 1997 Oct; 56(6):1674-5. PubMed ID: 9351433
[No Abstract] [Full Text] [Related]
12. Prostate-cancer screening--what the U.S. Preventive Services Task Force left out.
Brett AS; Ablin RJ
N Engl J Med; 2011 Nov; 365(21):1949-51. PubMed ID: 22029759
[No Abstract] [Full Text] [Related]
13. PSA-based screening for localised prostate cancer. Uncertain benefits, potential adverse consequences, and many outstanding questions.
Prescrire Int; 2009 Oct; 18(103):225. PubMed ID: 19882799
[No Abstract] [Full Text] [Related]
14. New prostate cancer screening guidelines.
Wartinger DD
J Am Osteopath Assoc; 1993 Jul; 93(7):736. PubMed ID: 7690013
[No Abstract] [Full Text] [Related]
15. The United States Preventive Services Task Force recommendation against prostate-specific antigen screening--point.
Ablin RJ
Cancer Epidemiol Biomarkers Prev; 2012 Mar; 21(3):391-4. PubMed ID: 22315362
[No Abstract] [Full Text] [Related]
16. Limitations and use of PSA derivatives in the screening and risk stratification of prostate cancer.
Loeb S; Carter HB
Urol Oncol; 2009; 27(6):583-4. PubMed ID: 19879470
[No Abstract] [Full Text] [Related]
17. Comment on the US Preventive Services Task Force's draft recommendation on screening for prostate cancer.
Kwiatkowski M; Klotz L; Hugosson J; Recker F
Eur Urol; 2012 Apr; 61(4):851-4. PubMed ID: 22285762
[No Abstract] [Full Text] [Related]
18. [Screening for prostatic cancer].
Pushkar' DIu; Govorov AV; Bormotin AV
Urologiia; 2003; (1):10-5. PubMed ID: 12621959
[TBL] [Abstract][Full Text] [Related]
19. Controversy over prostate-specific antigen screening has shifted from mortality to overtreatment issues.
Ito K
Int J Urol; 2009 Sep; 16(9):711-12. PubMed ID: 19777638
[No Abstract] [Full Text] [Related]
20. ERSPC and PLCO prostate cancer screening studies: what are the differences?
Schröder FH; Roobol MJ
Eur Urol; 2010 Jul; 58(1):46-52. PubMed ID: 20362385
[No Abstract] [Full Text] [Related]
[Next] [New Search]
